These results, for the six months ending 31 December 2025, have enabled the board to declare an 11% increase in the interim dividend to 15p per share and announce the commencement of a $25m (c. £18.8m) share buyback programme.

The company’s growth is increasingly driven by its Trisus platform and the strategic integration of artificial intelligence. Chief executive Keith Neilson said: “High levels of expansion sales, healthy NRR and an increasing 340B Shelter opportunity underpin our confidence in a positive second half performance.

“The increasing levels of competitive wins and takeouts we have seen in the first half of the year demonstrate the importance of the Trisus platform, the benefit of our independence to our hospital customers and our ability to leverage AI in combination with our extensive proprietary data sets to deliver the solutions our customers need, when they need them. These unique strengths underpin future revenue growth acceleration and sustainable, long-term value generation.

“The US healthcare market continues to evolve at pace, and with each new piece of legislation or change, the need for data-led insights and a secure and scalable technology partner grows. We have never been more confident in the vital role we play in enabling our customers to navigate these changes with confidence, while maintaining their financial strength and delivery of care. This is a hugely powerful motivator for all of us at The Craneware Group.

“With our wealth of proprietary data, deep industry expertise, longstanding and extensive customer base, and growing AI capabilities, the Board looks to the future with confidence.”

A key driver of recent success has been the expansion of the company’s alliance with Microsoft, which has accelerated the deployment of AI-enhanced tools for labour productivity and reimbursement intelligence.

Financial metrics remain strong across the board, with adjusted EBITDA rising 10% to $33.4m (c. £25m) and statutory profit before tax jumping 29% to $13m (c. £9.8m). Craneware’s “land and expand” strategy continues to yield results, evidenced by a healthy net revenue retention rate of 103%. Notably, the period saw a significant increase in competitive “takeouts”, with new customer wins rising to 12% of total new sales compared to just 2% in the previous year.

Despite the postponement of a US 340B rebate pilot programme, Craneware remains confident in its outlook for the remainder of the financial year. The company’s balance sheet is underpinned by $71.2 million in cash and a 26% reduction in bank debt to $23.4 million. With an addressable revenue opportunity estimated at over $1.6 billion within its existing customer base alone, the board expects to meet full-year market expectations while pursuing further growth through innovation and potential targeted acquisitions.